Merck, SML1628-5MG, LMT-28

Biochem/physiol Actions
LMT-28 is an IL-6 antagonist that targets the IL-6 Receptor β subunit, Glycoprotein 130 (gp130).
LMT-28 is an IL-6 antagonist that targets the IL-6 Receptor β subunit, Glycoprotein 130 (gp130). Its binding to gp130) results in inhibition of IL-6 activation, and downregulation of levels of p-STAT3. LMT-28 was shown to stimulate phosphorylation of STAT3 and JAK2 protein. IL-6 dysregulation is involved in inflammation and cancers. LMT-28 had inhbitory activity against IL-6–dependent TF-1 cell proliferation and also had therapeutic effect against pancreatitis.
LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6). Orally administered LMT-28 reduced arthritis and acute pancreatitis stimulated by collagen in mice pathologic models.